The White House has signalled its intention to press ahead with proposals to force drugmakers to include drug pricing information in direct-to-consumer advertising (DTC), despite the apparent inability of Congress to sign up to the idea.
In a speech in Washington DC on Monday, US Health Secretary Alex Azar reportedly said that drugmakers would be required to quote the list price of a thirty day supply of drugs provided through Medicaid or Medicare.
Some analysts have questioned whether adding list prices to adverts would be useful for patients, given that the list price is normally the starting point for a negotiation with payers and providers, and would likely not be the same as the product’s sticker price.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze